A5067669304- Prostate Cancer Diagnosis and Treatment
- Prostate Cancer Treatment and Research
- Bladder and Urothelial Cancer Treatments
- Urologic and reproductive health conditions
- Urological Disorders and Treatments
- Genital Health and Disease
- Urinary and Genital Oncology Studies
- Radiomics and Machine Learning in Medical Imaging
- MRI in cancer diagnosis
- Renal cell carcinoma treatment
- Sexual function and dysfunction studies
- Ureteral procedures and complications
- Pediatric Urology and Nephrology Studies
- Urinary Bladder and Prostate Research
- Cancer, Lipids, and Metabolism
- Renal and Vascular Pathologies
- Reconstructive Surgery and Microvascular Techniques
- Colorectal Cancer Screening and Detection
- Advanced MRI Techniques and Applications
- Radiopharmaceutical Chemistry and Applications
- Hormonal and reproductive studies
- Renal and related cancers
- Medical Imaging Techniques and Applications
- Viral-associated cancers and disorders
- Health Systems, Economic Evaluations, Quality of Life
University of Turin
2016-2025
Fondazione Ricerca Molinette
2010-2025
Azienda Ospedaliera Citta' della Salute e della Scienza di Torino
2015-2023
Azienda Sanitaria Unità Locale di Reggio Emilia
2022
Istituti di Ricovero e Cura a Carattere Scientifico
2022
Essen University Hospital
2022
Ospedale Policlinico San Martino
2022
TH Bingen University of Applied Sciences
2022
University of Tübingen
2022
Azienda Ospedaliero Universitaria San Giovanni Battista
2008-2021
Objectives To determine if a re‐transurethral resection (TUR), in the presence or absence of muscle at first TUR patients with T1‐high grade (HG)/Grade 3 (G3) bladder cancer, makes difference recurrence, progression, cancer specific (CSS) and overall survival (OS). Patients methods In large retrospective multicentre cohort 2451 T1‐HG/G3 initially treated bacille Calmette–Guérin, 935 (38%) had re‐TUR. According to specimen primary TUR, were divided four groups: group 1 (no muscle, no re‐TUR),...
No AccessJournal of UrologyAdult Urology1 Oct 2019Salvage Radical Prostatectomy for Recurrent Prostate Cancer: Morbidity and Functional Outcomes from a Large Multicenter Series Open versus Robotic Approaches Paolo Gontero, Giancarlo Marra, Alessio, Claudia Filippini, Marco Oderda, Fernando Munoz, Estefania Linares, Rafael Sanchez-Salas, Ben Challacombe, Prokar Dasgupta, Sanchia Goonewardene, Rick Popert, Declan Cahill, David Gillatt, Raj Persad, Juan Palou, Steven Joniau, Thierry Piechaud,...
Bladder cancer (BC) is the most frequent malignancy of urinary tract with a high incidence in men and smokers. Currently, there are no non-invasive markers useful for BC diagnosis subtypes classification that could overcome invasive procedures such as cystoscopy. Dysregulated miRNA profiles have been associated numerous cancers, including BC. Cell-free miRNAs abundantly present variety biofluids urine make them promising candidates biomarker discovery. In study, identification fingerprints...
BACKGROUND Antioxidants effectiveness in prostate cancer (PCa) chemoprevention has been severely questioned, especially after the recent results of Selenium and Vitamin E Cancer Prevention Trial. We present a double‐blind randomized controlled trial (dbRCT) on pharmacokinetic, clinical, molecular activity dietary supplements containing lycopene, selenium, green tea catechins (GTCs) men with multifocal high grade prostatic intraepithelial neoplasia (mHGPIN) and/or atypical small acinar...
Objectives To report the results from a prospective multicentric study of patients with Peyronie's disease ( PD ) treated ‘sliding’ technique ST ). Patients and Methods From June 2010 to January 2014, 28 consecutive affected by stable severe penile shortening end‐stage erectile dysfunction ED were enrolled in three European tertiary referral centres. The validated International Index Erectile Function IIEF questionnaire, Sexual Encounter Profile SEP Questions 2 3, questionnaire PDQ completed...
Most bladder cancer (BC) patients need life-long, invasive and expensive monitoring treatment, making it a serious burden on the health system. Thus, there is pressing for an accurate test to assist diagnosis surveillance of BC as alternative cystoscopy. Mutations in human TERT, FGFR3, PIK3CA, RAS genes have been proposed potential molecular markers tumor. Their concomitant presence urine samples has not fully explored.We investigated panel mutations DNA from exfoliated urinary cells 255 at...
Increasing use of multiparametric magnetic resonance imaging (mpMRI) has come with heterogeneity in image quality. The Prostate Imaging Quality (PI-QUAL) score is under scrutiny to assess its usefulness predicting clinical outcomes.To compare upstaging localized disease on mpMRI (mrT2) locally invasive radical prostatectomy (RP) specimens (≥pT3a) relation PI-QUAL.Patients treated RP between 2015 and 2020 who underwent 1.5-3-T within 6 mo before surgery had systematic mpMRI-US targeted...
Bacillus Calmette-Guérin and intravesical chemotherapy represent viable adjuvant options for intermediate risk nonmuscle invasive bladder cancer. Although bacillus is perceived as less tolerable than chemotherapy, to our knowledge no comparative studies have addressed quality of life issues. We compared the patients with cancer who received gemcitabine or 1/3 dose Calmette-Guérin.Our multicenter, prospective, randomized, phase II study included 120 Of these 88 remained assessable at 1-year...
To externally validate the currently available nomograms for predicting lymph node invasion (LNI) in patients with prostate cancer (PCa) and to assess potential risk of complications extended pelvic dissection (ePLND) when using recommended threshold.A total 14 921 patients, who underwent radical prostatectomy ePLND at eight European tertiary referral centres, were retrospectively identified. After exclusion incomplete biopsy or pathological data, 12 009 included. Of these, 609 had undergone...
To assess the outcomes of multiparametric magnetic resonance imaging (mpMRI) transperineal targeted fusion biopsy (TPFBx) under local anaesthesia.We prospectively screened 1327 patients with a positive mpMRI undergoing TPFBx (targeted cores and systematic cores) anaesthesia, at two tertiary referral institutions, between September 2016 May 2019, for inclusion in present study. Primary were detection clinically significant prostate cancer (csPCa) defined as (1) International Society...
Bladder cancer (BC) is the tenth most frequent worldwide. Due to need for recurrent cystoscopies and lack of non-invasive biomarkers, BC associated with a high management burden. In this respect, small non-coding RNAs (sncRNAs) have been investigated in urine as possible biomarkers BC, but plasma their potential has not yet defined. The expression levels sncRNAs contained extracellular vesicles (EVs) from 47 men 46 healthy controls were assessed by next-generation sequencing. sncRNA profiles...
Objective To describe the trend in surgical volume urology Italy during coronavirus disease 2019 (COVID-19) outbreak, as a result of abrupt reorganisation Italian national health system to augment care provision symptomatic patients with COVID-19. Methods A total 33 urological units physicians affiliated AGILE consortium (Italian Group for Advanced Laparo-Endoscopic Surgery; www.agilegroup.it) were surveyed. Urologists asked report amount elective procedures week-by-week, from beginning...
<b><i>Purpose:</i></b> The coronavirus disease 2019 (COVID-19) pandemic has put a substantial burden on the Italian healthcare system, resulting in restructuring of hospitals to care for COVID-19 patients. However, this likely impacted access patients experiencing other conditions. We aimed quantify impact with urgent/emergent urological conditions throughout Italy. <b><i>Materials and Methods:</i></b> A questionnaire was sent 33 units AGILE...
To evaluate and compare the incidence of cardiovascular (CV) events in a large contemporary cohort patients diagnosed with prostate cancer (PCa) treatment GnRH agonists or antagonists.An Italian observational retrospective study based on administrative databases three local health units two Regions was performed. PCa treated antagonist were included between January 01, 2013 December 31, 2016. Index date (ID) first agonist/antagonist prescription during inclusion period. Follow-up from ID to...